Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for ATHXQ.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
September 30, 2023 -3.847M
June 30, 2023 -4.585M
March 31, 2023 -5.966M
December 31, 2022 -11.96M
September 30, 2022 -10.38M
June 30, 2022 -16.44M
March 31, 2022 -20.17M
December 31, 2021 -19.33M
September 30, 2021 -19.66M
June 30, 2021 -20.10M
March 31, 2021 -17.09M
December 31, 2020 -17.28M
September 30, 2020 -19.69M
June 30, 2020 -12.74M
March 31, 2020 -12.10M
December 31, 2019 -10.15M
September 30, 2019 -8.214M
June 30, 2019 -11.44M
March 31, 2019 -5.515M
December 31, 2018 -4.566M
September 30, 2018 -7.498M
June 30, 2018 4.392M
March 31, 2018 -5.678M
December 31, 2017 -6.143M
September 30, 2017 -6.814M
Date Value
June 30, 2017 -5.681M
March 31, 2017 -5.38M
December 31, 2016 -6.284M
September 30, 2016 -5.499M
June 30, 2016 -6.47M
March 31, 2016 7.322M
December 31, 2015 -5.359M
September 30, 2015 -3.681M
June 30, 2015 -5.84M
March 31, 2015 1.116M
December 31, 2014 -6.134M
September 30, 2014 -6.249M
June 30, 2014 -6.131M
March 31, 2014 -7.277M
December 31, 2013 -4.514M
September 30, 2013 -5.721M
June 30, 2013 -6.436M
March 31, 2013 -6.113M
December 31, 2012 -3.643M
September 30, 2012 -3.614M
June 30, 2012 -4.991M
March 31, 2012 -5.417M
December 31, 2011 -4.482M
September 30, 2011 -4.161M
June 30, 2011 -4.043M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. -177.47M
Oncolytics Biotech, Inc. -8.066M
Sangamo Therapeutics, Inc. -19.28M
Sarepta Therapeutics, Inc. 197.07M
Anixa Biosciences, Inc. -1.741M